=> d l6
L6 HAS NO ANSWERS
L6 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 1
NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE

=> d his l8

(FILE 'REGISTRY' ENTERED AT 08:59:19 ON 28 OCT 2008)
L8 28 S L6 FUL

=> d his l11

(FILE 'CAPLUS' ENTERED AT 09:04:34 ON 28 OCT 2008)

FILE 'REGISTRY' ENTERED AT 09:05:20 ON 28 OCT 2008
L11 2 S 1005786-02-6 OR 1023814-83-6

=> d his l12

(FILE 'CAPLUS' ENTERED AT 09:06:03 ON 28 OCT 2008)
L12 1 S L11

=> d bib abs hitstr

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2008:160676 CAPLUS
DN 148:239217
TI Preparation of fused heterocyclic compounds as apoptosis signal regulating kinase 1 (ASK1) inhibitors
IN Uchikawa, Osamu; Sakai, Nozomu; Terao, Yoshito; Suzuki, Hideo
PA Takeda Pharmaceutical Company Limited, Japan
SO PCT Int. Appl., 340pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 2008016131 A1 20080207 WO 2007-JP65227 20070803
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRAI JP 2006-213960 A 20060804
OS MARPAT 148:239217
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Fused heterocyclic compds. such as imidazopyridine and imidazopyridazine derivs. [I; R1-R6 = H or a substituent; X = :N, :C(Z); Z = H or a substituent; When X is :C(Z), Z and R6 may combine together to form an optionally substituted ring together with the carbon atom to which they are bonded.] or salts thereof are prepared These compds. have ASK1 inhibitory activity and are thus useful as pharmaceutical products for prevention and treatment of diabetes or inflammatory diseases, e.g. chronic obstructive pulmonary disease (COPD). Thus, a mixture of 11 mg 2-amino-6-phenylimidazo[1,2-b]pyridazine and 10 mg 4-cyanobenzoyl chloride in 0.5 mL DMF was stirred at room temperature for 14 h to give, after workup and
purification using HPLC, 4-cyano-N-(6-phenylimidazo[1,2-b]pyridazin-2-yl)benzamide trifluoroacetate (II).
N-(6-Chloroimidazo[1,2-a]pyridin-2-yl)-4-[1,1-dimethyl-2-oxo-2-[[2-(1H-tetrazol-5-yl)ethyl]amino]ethyl]benzamide (III) showed IC50 of μg/mL against 13 nM against recombinant human ASK1. A gelatine capsule and a tablet formulation containing II were prepared

IT 1005786-02-6P, 4-(3-Hydroxy-1,1-dimethylpropyl)benzoic acid ethyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of fused heterocyclic compds. as apoptosis signal regulating kinase 1 (ASK1) inhibitors for prevention and treatment of diabetes or inflammatory diseases)

RN 1005786-02-6 CAPLUS

CN Benzoic acid, 4-(3-hydroxy-1,1-dimethylpropyl)-, ethyl ester (CA INDEX NAME)



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT